HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senomyx

This article was originally published in The Rose Sheet

Executive Summary

La Jolla, Calif.-based fragrance and flavor molecule developer withdraws initial public offering based on "unfavorable market conditions," the firm said in a Sept. 5 notice to the Securities and Exchange Commission. The company's IPO, filed in February, proposed raising up to $80 mil. The offering was underwritten by Deutsche Banc Alex Brown, Bear, Stearns & Co. and CIBC World Markets. Senomyx aims to assemble a proprietary technology platform to "enhance and industrialize" the flavor and fragrance molecule discovery process using taste and smell receptor genes, according to the registration statement. The early-stage company has entered into a product development collaboration with Kraft Foods

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel